Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease — Stella

Recruiting

Back to Persistent Corneal Epithelial Defect trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

University of Illinois at Chicago, Chicago, Illinois

Key details

Phase

Safety & dosing

Sponsor

University of Illinois at Chicago

Collaborators

National Eye Institute (NEI), National Institutes of Health (NIH)

Enrollment target

~24 participants

Started

August 2025

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov